The Pfizer/BioNTech booster vaccine provides 95.6% efficacy against COVID-19

The booster programmes, which have been initiated in numerous countries to fight the pandemic, have received their boost with results from the first Phase III controlled, randomised clinical trial.

The booster dose of Pfizer-BioNTech’s vaccine, Comirnaty, administered to 10,000 people over the age of 16 who completed the initial two-dose regimen, has been shown to restore vaccine protection against COVID-19 to the high levels reached after the following dose.

The third dose caused a relative vaccine efficacy of ninety-five-point-six per cent compared to those who didn’t receive a booster, on average given eleven months after the second dose.

After 2.5 months, recipients of the booster shot were followed up on, and there were five cases of COVID-19 in the booster group and 109 cases in the non-boosted group.

The trial took place when the Delta version of SARS-CoV-2, which is substantially more transmissible, was the prevalent strain circulating.

CEO and Chairman of Pfzier, Albert Bourla, stated: “These results provide further evidence of the benefits of boosters. We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic.”